Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 1,100 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.00, for a total transaction of $94,600.00. Following the transaction, the chief marketing officer now owns 264,900 shares in the company, valued at $22,781,400. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jane Huang also recently made the following trade(s):

  • On Thursday, November 16th, Jane Huang sold 600 shares of Beigene stock. The shares were sold at an average price of $85.00, for a total transaction of $51,000.00.
  • On Monday, November 20th, Jane Huang sold 1,600 shares of Beigene stock. The shares were sold at an average price of $86.25, for a total transaction of $138,000.00.

Beigene Ltd (NASDAQ BGNE) traded up $13.50 during mid-day trading on Tuesday, hitting $94.50. 1,747,800 shares of the company were exchanged, compared to its average volume of 203,371. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33. Beigene Ltd has a 1-year low of $26.43 and a 1-year high of $118.95.

Beigene (NASDAQ:BGNE) last released its quarterly earnings data on Monday, November 13th. The company reported $2.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same period last year, the business earned ($1.08) EPS. research analysts forecast that Beigene Ltd will post -2.04 earnings per share for the current fiscal year.

BGNE has been the topic of a number of research analyst reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Beigene in a research note on Monday, August 7th. They set a “buy” rating and a $81.00 price objective on the stock. Zacks Investment Research downgraded shares of Beigene from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Goldman Sachs Group reissued a “buy” rating and set a $86.00 target price (up from $43.00) on shares of Beigene in a report on Tuesday, August 15th. Maxim Group reissued a “buy” rating and set a $77.00 target price on shares of Beigene in a report on Monday, September 11th. Finally, Morgan Stanley reissued an “overweight” rating and set a $95.00 target price (up from $87.00) on shares of Beigene in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $96.67.

Several hedge funds have recently added to or reduced their stakes in the stock. Hillhouse Capital Management Ltd. grew its position in Beigene by 172.6% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock valued at $167,433,000 after buying an additional 2,355,906 shares in the last quarter. Orbimed Advisors LLC grew its position in Beigene by 2.0% in the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock valued at $135,925,000 after buying an additional 26,200 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in Beigene in the 3rd quarter valued at about $62,076,000. Artal Group S.A. grew its position in Beigene by 10.1% in the 2nd quarter. Artal Group S.A. now owns 400,000 shares of the company’s stock valued at $18,000,000 after buying an additional 36,714 shares in the last quarter. Finally, Myriad Asset Management Ltd. grew its position in Beigene by 16.6% in the 2nd quarter. Myriad Asset Management Ltd. now owns 385,585 shares of the company’s stock valued at $17,351,000 after buying an additional 54,900 shares in the last quarter. 55.34% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/05/jane-huang-sells-1100-shares-of-beigene-ltd-bgne-stock.html.

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.